Serum Uric Acid Monitoring and Management with Febuxostat

Target Serum Uric Acid Levels

• The European League Against Rheumatism recommends a primary therapeutic target of serum uric acid <6 mg/dL (360 μmol/L), which must be maintained lifelong 2, 3
• For patients with severe gout (tophi, chronic arthropathy, or frequent attacks), the European League Against Rheumatism recommends targeting a lower level of <5 mg/dL (300 μmol/L) until complete crystal dissolution occurs 2, 3
• The European League Against Rheumatism advises avoiding maintaining serum uric acid <3 mg/dL long-term due to potential concerns about neurodegenerative effects 3

Long-Term Monitoring Strategy

• The American College of Rheumatology recommends rechecking serum uric acid levels every 6 months once the target is achieved and maintained, to ensure continued control 4
• Regular monitoring is essential because approximately 40% of successfully treated patients show recurrence of flares after changes in urate-lowering therapy, according to the American College of Rheumatology 4
• The American College of Rheumatology suggests that renal function should also be monitored every 6 months, as changes may necessitate dose adjustments 4

Common Pitfalls to Avoid

• The European League Against Rheumatism recommends against stopping monitoring after achieving target levels - lifelong maintenance below 6 mg/dL requires regular surveillance every 6 months 3, 4
• The American College of Rheumatology advises against reducing or discontinuing febuxostat based solely on symptom improvement without laboratory confirmation that serum uric acid remains below target 4
• The European League Against Rheumatism recommends continuing flare prophylaxis (colchicine or NSAIDs) for at least 6 months after starting febuxostat, regardless of serum uric acid levels 2